These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15017238)

  • 41. Hepatic failure with flutamide.
    Kackar RR; Desai HG
    Indian J Gastroenterol; 2003; 22(4):149-50. PubMed ID: 12962443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Ischemic colitis after taking flutamide].
    Barouk J; Doubremelle M; Faroux R; Schnee M; Lafargue JP
    Gastroenterol Clin Biol; 1998 Oct; 22(10):841. PubMed ID: 9854217
    [No Abstract]   [Full Text] [Related]  

  • 43. Flutamide-induced photosensitivity: is it a forme fruste of lupus?
    Kaur C; Thami GP
    Br J Dermatol; 2003 Mar; 148(3):603-4. PubMed ID: 12653768
    [No Abstract]   [Full Text] [Related]  

  • 44. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vitiliginous lesions after photosensitive dermatitis due to flutamide.
    Swoboda A; Kasche A; Baumstark J; Worret WI; Ring J; Eberlein-König B
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):681-2. PubMed ID: 17447984
    [No Abstract]   [Full Text] [Related]  

  • 46. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
    Green HJ; Pakenham KI; Headley BC; Yaxley J; Nicol DL; Mactaggart PN; Swanson CE; Watson RB; Gardiner RA
    BJU Int; 2004 May; 93(7):975-9. PubMed ID: 15142146
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response of bidimensionally measurable metastases to flutamide withdrawal in a patient with advanced prostate cancer.
    Warren GP; Roth BJ
    Indiana Med; 1996; 89(3):274-7. PubMed ID: 8675981
    [No Abstract]   [Full Text] [Related]  

  • 48. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.
    Tanvetyanon T
    Cancer; 2005 Jan; 103(2):237-41. PubMed ID: 15597384
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Flutamide photosensitivity--residual vitiliginous lesions.
    Vilaplana J; Romaguera C; Azón A; Lecha M
    Contact Dermatitis; 1998 Feb; 38(2):68-70. PubMed ID: 9506217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):327-33. PubMed ID: 18707821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
    Masue N; Hasegawa Y
    Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.
    Wright JL; Lin DW; Dewan P; Montgomery RB
    Int J Urol; 2005 Nov; 12(11):1012-3. PubMed ID: 16351664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Editorial comment on: continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study.
    Albrecht W
    Eur Urol; 2008 Aug; 54(2):390-1. PubMed ID: 18339476
    [No Abstract]   [Full Text] [Related]  

  • 55. Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia.
    Kalff A; Shortt J; Farr J; McLennan R; Lui A; Scott J; Spencer A
    Haematologica; 2008 Jan; 93(1):e16-7. PubMed ID: 18166770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
    BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk?
    Roach M
    J Clin Oncol; 2007 Nov; 25(33):5325-6; author reply 5326. PubMed ID: 18024880
    [No Abstract]   [Full Text] [Related]  

  • 58. Bicalutamide-associated fulminant hepatotoxicity.
    O'Bryant CL; Flaig TW; Utz KJ
    Pharmacotherapy; 2008 Aug; 28(8):1071-5. PubMed ID: 18657023
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Acute flutamide-induced hepatitis].
    Nicolás D; Pérez-EbrI ML; Sarrión JV; Nos P
    Gastroenterol Hepatol; 1999 May; 22(5):262-3. PubMed ID: 10396113
    [No Abstract]   [Full Text] [Related]  

  • 60. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.
    Jenkins VA; Bloomfield DJ; Shilling VM; Edginton TL
    BJU Int; 2005 Jul; 96(1):48-53. PubMed ID: 15963119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.